The Cooper Companies, Inc (COO)vsEli Lilly and Company (LLY)
COO
The Cooper Companies, Inc
$63.51
-1.41%
HEALTHCARE · Cap: $11.30B
LLY
Eli Lilly and Company
$1,354.49
-0.75%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1941% more annual revenue ($86.46B vs $4.24B). LLY leads profitability with a 31.9% profit margin vs 13.5%. COO appears more attractively valued with a PEG of 0.56. LLY earns a higher WallStSmart Score of 74/100 (B).
COO
Strong Buy71
out of 100
Grade: B
LLY
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.9%
Fair Value
$207.07
Current Price
$63.51
$143.56 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 357.1% YoY
Growing faster than its price suggests
Strong operational efficiency at 20.8%
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 7.8B in free cash flow
Areas to Watch
0.6% revenue growth
ROE of 6.8% — below average capital efficiency
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : COO
The strongest argument for COO centers on Price/Book, EPS Growth, PEG Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : COO
The primary concerns for COO are Revenue Growth, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
COO profiles as a value stock while LLY is a growth play — different risk/reward profiles.
COO carries more volatility with a beta of 0.82 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 71/100), backed by strong 31.9% margins and 38.6% revenue growth. COO offers better value entry with a 59.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Cooper Companies, Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?